Questions EMERGE as Biogen claims aducanumab turnaround
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The EMERGE and ENGAGE trials of Aducanumab produced inconsistent results: cognitive decline slowed significantly at the highest dose in EMERGE but not in ENGAGE.
“Two clinical trials with anti-Aβ monoclonal antibody Aducanumab10, EMERGE and ENGAGE, have recently yielded inconsistent results, since cognitive decline was significantly slowed down in patients receiving the highest dose (10 mg/kg) in the EMERGE cohort but not in the ENGAGE cohort11.”
From Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) · cites this paper as [11]
Aducanumab therapy appears to be able to slow the course of Alzheimer's disease in its early stages.
“Aducanumab therapy appears to be able to slow the course of the disease in its early stages.”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [32]
Although aducanumab has been approved by the FDA, its clinical effectiveness is still controversial.
“Although this drug has been approved by the FDA, its clinical effectiveness is still controversial [32].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · see citing works
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · see citing works
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338 · see citing works
Thompson, B. (1989) · Measurement and Evaluation in Counseling and Development · doi:10.1080/07481756.1990.12022905 · Cited by 89 · see citing works
P3‐046: Detection of memory decline in “healthy” community volunteers within 6 months
Darby, D., Fredrickson, J., Fredrickson, A., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1223 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · see citing works
Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy
Da Mesquita, S., Papadopoulos, Z., Dykstra, T., Brase, L., Farias, F. G., Wall, M., Jiang, H., Kodira, C. D., de Lima, K. A., Herz, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03489-0 · Cited by 431 · see citing works
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works
Liu, H., Ye, M., & Guo, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01688 · Cited by 116 · see citing works
The need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113 · see citing works
Self-citationYeo-Teh, N. S. L., & Tang, B. L. (2023) · Science and Engineering Ethics · doi:10.1007/s11948-022-00422-0 · Cited by 28 · see citing works
Fitzgerald, G. S., Chuchta, T. G., & McNay, E. C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14160 · Cited by 22 · see citing works
- Authors
- Howard, R., & Liu, K. Y.
- Affiliations
- University College London (GB)
- Corresponding author
- Howard, Robert
- Venue
- Nature Reviews Neurology
- Published
- 2019-11-29
- Volume
- 16
- Issue
- 2
- Pages
- 63-64
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2990201855
- Cited by
- 123
- References
- 6
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 15 · 2022: 24 · 2021: 35 · 2020: 29 · 2019: 1
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Medical Research Council (MR/S021418/1)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, Biogen, futility analysis, FDA drug approval, anti-amyloid therapy, clinical trial data
- MeSH terms
- Alzheimer Disease, Amyloidosis, Humans, United States, United States Food and Drug Administration, Treatment Outcome, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
